ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

Bookmark and Share
Published: 10 Dec 2020
Views: 112
Rating:
Save
Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany

Prof Andreas Hochhaus speaks to ecancer in an online interview for the virtual ASH 2020 meeting about the results of the phase III ASCEMBL study.

He explains that the study was a multi-centre, open-label study looking at the safety and efficacy of asciminib vs bosutinib in patients with chronic myeloid leukaemia (CML).

Prof Hochhaus reports that asciminib showed improved safety and efficacy compared to bosutinib, These results support the use of asciminib as a new treatment option in CML, particularly in patients with who have had resistance or intolerance to at least two prior tyrosine kinase inhibitors.